Halimi S, Benhamou P Y, Charras H
Service d'Endocrinologie, Diabétologie et Maladies de la Nutrition, CHU de Grenoble, France.
Diabete Metab. 1993 Dec;19(5 Suppl):518-22.
Among the long term complications of diabetes, leg and foot problems frequently associated with chronic nonhealing wounds constitute a heavy economic cost previously evaluated in some countries. This specific cost has not yet been calculated in France. This study represents the first "estimation" of the frequency and cost of these complications in our country. Methodological obstacles must be considered related to a large variety of clinical situations all covered by the word "diabetic foot", neurotrophic or ischemic origin, and the heterogeneity of the therapeutical approach more or less expensive. We have estimated the incidence of leg and foot problems about 50,000 to 60,000 per years, 20,000 to 25,000 requiring an inpatient treatment for a neurotrophic complication and 10,000 to 15,000 for an ischemic problem (frequently followed by a limited or a large amputation). The annual total cost, direct plus indirect, calculated on this basis should be: 3,750 millions of francs/year (about 700 millions of US $). This value must be compared to the total cost of diabetes in France 12,000 to 18,000 millions of francs/year when considering 1 to 1.5 million diabetic patients. Thus leg and foot problems appear to constitute a prominent part of the economical cost of diabetes in our country as in others developed countries. Multidisciplinary and specialized structures for the care and prevention of such complications of diabetes must be developed as new therapeutical approaches to reduce this incidence, the duration of healing and the risk of relapse.
在糖尿病的长期并发症中,腿部和足部问题常与慢性不愈合伤口相关,在一些国家,这构成了巨大的经济成本。法国尚未计算过这一特定成本。本研究首次对我国这些并发症的发生率和成本进行了“估算”。必须考虑到方法上的障碍,因为“糖尿病足”涵盖了各种各样的临床情况,包括神经营养性或缺血性病因,以及治疗方法的异质性,其成本或多或少有所不同。我们估计每年腿部和足部问题的发生率约为5万至6万例,其中2万至2.5万例因神经营养性并发症需要住院治疗,1万至1.5万例因缺血性问题(常随后进行有限或大范围截肢)。在此基础上计算出的每年直接和间接总成本应为:37.5亿法郎/年(约7亿美元)。当考虑到100万至150万糖尿病患者时,这一数值必须与法国糖尿病的总成本120亿至180亿法郎/年进行比较。因此,与其他发达国家一样,腿部和足部问题在我国似乎构成了糖尿病经济成本的一个突出部分。必须建立多学科和专门的机构来护理和预防糖尿病的此类并发症,作为新的治疗方法以降低其发生率、愈合时间和复发风险。